- Medline shareholders including Blackstone, Carlyle, Hellman & Friedman, the Abu Dhabi Investment Authority and GIC raised $2.1 billion in a share sale, Bloomberg reported, citing a company statement on Wednesday. The sellers sold 60 million shares at $35.50 apiece.
- Medline will not receive any proceeds from the offering. The selling stockholders granted underwriters an option to buy up to an additional 9 million shares.
- The company has agreed to buy back up to $200 million of its shares as part of the deal. Goldman Sachs, Morgan Stanley, Bank of America and JPMorgan were global coordinators and joint bookrunners.
- Shares of Medline fell 3.8% on Tuesday, before the pricing was announced. The sale gives the private-equity backers a way to cut their holdings in a US-listed company in a market where the AI trade has been under pressure.
What Happened?
A group of Medline’s private-equity and sovereign-wealth backers sold 60 million shares at $35.50 each, raising $2.1 billion, according to a statement cited by Bloomberg. Medline itself will not receive proceeds but plans to repurchase up to $200 million of its stock. Underwriters hold an option on up to 9 million more shares.
Why It Matters?
Secondary sales by sponsors after an IPO are a common way for large holders to reduce their stake, and the pricing shows how much demand exists for the stock after Tuesday’s 3.8% decline. The company’s buyback offsets part of the supply.
What’s Next?
Watch how Medline trades relative to the $35.50 offer price once the sale settles, whether underwriters exercise the 9 million share option, and whether the sponsors return with further sales as lock-ups and market conditions allow. The pace of such follow-on offerings will indicate how receptive investors are to large block sales while tech valuations remain unsettled.
Affected Tickers and Coins: MDLN, BX, CG, GS, MS, BAC, JPM
Source: Bloomberg












